Climb Bio (CLYM) Shares Outstanding (2020 - 2026)

Climb Bio has reported Shares Outstanding for 7 years, with the latest figure at $47.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding fell 29.31% year-over-year to $47.8 million; the trailing twelve-month figure through Mar 2026 stood at $47.8 million (down 29.31% YoY), and the FY2025 full-year result was $47.8 million, down 28.98% from the prior year.
• Shares Outstanding for Q1 2026 stood at $47.8 million, roughly flat from $47.8 million in the prior quarter.
• The five-year high for Shares Outstanding was $68.2 million in Q3 2025, with the low at $26.2 million in Q1 2022.
• Historically, Shares Outstanding has averaged $43.6 million across 5 years, with a median of $27.7 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding soared 654.38% — and 2026, when it slipped 29.31%.
• Climb Bio's Shares Outstanding stood at $26.4 million in 2022, then climbed by 4.68% to $27.6 million in 2023, then jumped by 143.45% to $67.3 million in 2024, then slipped by 28.98% to $47.8 million in 2025, then rose by 0.0% to $47.8 million in 2026.
• The last three Shares Outstanding figures came in at $47.8 million (Q1 2026), $47.8 million (Q4 2025), and $68.2 million (Q3 2025), per Business Quant data.